Lastly, though local activation of tumor-specific CD8+ effector T cells is responsible for durable anti-tumor immunity by CDNs via type I IFNs production [62], CDNs also activate NK cells to kill CD8+ T cell-resistant tumors [29,86]. This evidence concerns the gene CD8A and neoplasm.